Researchers Detail Favorable Zevalin Data At ASH, But Also Medicare Concern
Executive Summary
ATLANTA - No sooner did Medicare announce it will cap funding for two approved radioimmunotherapies than an international phase III trial is reporting that one of them, Zevalin, can prolong progression-free survival by two years in relapsed follicular non-Hodgkin's lymphoma
You may also be interested in...
CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted
After winning a short-term reprieve from Medicare's payment cap on radioimmunotherapies, Cell Therapeutics will focus on convincing CMS to pay for those drugs under Part B's average sales price formula
CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted
After winning a short-term reprieve from Medicare's payment cap on radioimmunotherapies, Cell Therapeutics will focus on convincing CMS to pay for those drugs under Part B's average sales price formula
Medicare Rates For Hospital Outpatient Drugs Lowered To ASP+5% In 2008
Medicare will reimburse drugs provided through hospital outpatient departments in 2008 at a lower Part B rate than this year, and, for the first time since the start of the average sales price methodology, lower than the rate set for products provided in physician offices